Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital
Design Retrospective cohort study.Setting Regional hospital-based oncology database of approximately 2 million patients in England.Participants Patients aged ≥18 years with a diagnosis of BC, NSCLC or PC as well as BM between 1 January 2007 and 31 December 2018, with follow-up to 30 June 2020 or dea...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-05-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/5/e069214.full |
| _version_ | 1797831144590278656 |
|---|---|
| author | Matthew Thompson Peter Egger Sue Cheeseman Majid Riaz Bethany Levick Ali Abbasi Anouchka Seesaghur Joshua Warden Peter McMahon |
| author_facet | Matthew Thompson Peter Egger Sue Cheeseman Majid Riaz Bethany Levick Ali Abbasi Anouchka Seesaghur Joshua Warden Peter McMahon |
| author_sort | Matthew Thompson |
| collection | DOAJ |
| description | Design Retrospective cohort study.Setting Regional hospital-based oncology database of approximately 2 million patients in England.Participants Patients aged ≥18 years with a diagnosis of BC, NSCLC or PC as well as BM between 1 January 2007 and 31 December 2018, with follow-up to 30 June 2020 or death; BM diagnosis ascertained from recorded medical codes and unstructured data using natural language processing (NLP).Main outcomes measures Initiation or non-initiation of BTA following BM diagnosis, time from BM diagnosis to BTA initiation, time from first to last BTA, time from last BTA to death.Results This study included 559 BC, 894 NSCLC and 1013 PC with BM; median age (Q1–Q3) was 65 (52–76), 69 (62–77) and 75 (62–77) years, respectively. NLP identified BM diagnosis from unstructured data for 92% patients with BC, 92% patients with NSCLC and 95% patients with PC. Among patients with BC, NSCLC and PC with BM, 47%, 87% and 88% did not receive a BTA, and 53%, 13% and 12% received at least one BTA, starting a median 65 (27–167), 60 (28–162) and 610 (295–980) days after BM, respectively. Median (Q1–Q3) duration of BTA treatment was 481 (188–816), 89 (49–195) and 115 (53–193) days for patients with BC, NSCLC and PC. For those with a death record, median time from last BTA to death was 54 (26–109) for BC, 38 (17–98) for NSCLC and 112 (44–218) days for PC.Conclusion In this study identifying BM diagnosis from both structured and unstructured data, a high proportion of patients did not receive a BTA. Unstructured data provide new insights on the real-world use of BTA. |
| first_indexed | 2024-04-09T13:47:20Z |
| format | Article |
| id | doaj.art-afcc5b5dc1314a8bac8b61949c3ec775 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-04-09T13:47:20Z |
| publishDate | 2023-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-afcc5b5dc1314a8bac8b61949c3ec7752023-05-09T02:00:07ZengBMJ Publishing GroupBMJ Open2044-60552023-05-0113510.1136/bmjopen-2022-069214Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospitalMatthew Thompson0Peter Egger1Sue Cheeseman2Majid Riaz3Bethany Levick4Ali Abbasi5Anouchka Seesaghur6Joshua Warden7Peter McMahon8senior clinical scientistmedical statisticianREAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UKREAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK2IqviaCentre for Observational Research, Amgen Ltd Uxbridge, Uxbridge, Middlesex, UKCentre for Observational Research, Amgen Ltd, Uxbridge, UKReal World Studies, IQVIA Europe, London, UKReal World Studies, IQVIA Europe, London, UKDesign Retrospective cohort study.Setting Regional hospital-based oncology database of approximately 2 million patients in England.Participants Patients aged ≥18 years with a diagnosis of BC, NSCLC or PC as well as BM between 1 January 2007 and 31 December 2018, with follow-up to 30 June 2020 or death; BM diagnosis ascertained from recorded medical codes and unstructured data using natural language processing (NLP).Main outcomes measures Initiation or non-initiation of BTA following BM diagnosis, time from BM diagnosis to BTA initiation, time from first to last BTA, time from last BTA to death.Results This study included 559 BC, 894 NSCLC and 1013 PC with BM; median age (Q1–Q3) was 65 (52–76), 69 (62–77) and 75 (62–77) years, respectively. NLP identified BM diagnosis from unstructured data for 92% patients with BC, 92% patients with NSCLC and 95% patients with PC. Among patients with BC, NSCLC and PC with BM, 47%, 87% and 88% did not receive a BTA, and 53%, 13% and 12% received at least one BTA, starting a median 65 (27–167), 60 (28–162) and 610 (295–980) days after BM, respectively. Median (Q1–Q3) duration of BTA treatment was 481 (188–816), 89 (49–195) and 115 (53–193) days for patients with BC, NSCLC and PC. For those with a death record, median time from last BTA to death was 54 (26–109) for BC, 38 (17–98) for NSCLC and 112 (44–218) days for PC.Conclusion In this study identifying BM diagnosis from both structured and unstructured data, a high proportion of patients did not receive a BTA. Unstructured data provide new insights on the real-world use of BTA.https://bmjopen.bmj.com/content/13/5/e069214.full |
| spellingShingle | Matthew Thompson Peter Egger Sue Cheeseman Majid Riaz Bethany Levick Ali Abbasi Anouchka Seesaghur Joshua Warden Peter McMahon Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital BMJ Open |
| title | Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital |
| title_full | Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital |
| title_fullStr | Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital |
| title_full_unstemmed | Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital |
| title_short | Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital |
| title_sort | assessment of bone targeting agents use in patients with bone metastasis from breast lung or prostate cancer using structured and unstructured electronic health records from a regional uk based hospital |
| url | https://bmjopen.bmj.com/content/13/5/e069214.full |
| work_keys_str_mv | AT matthewthompson assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT peteregger assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT suecheeseman assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT majidriaz assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT bethanylevick assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT aliabbasi assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT anouchkaseesaghur assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT joshuawarden assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital AT petermcmahon assessmentofbonetargetingagentsuseinpatientswithbonemetastasisfrombreastlungorprostatecancerusingstructuredandunstructuredelectronichealthrecordsfromaregionalukbasedhospital |